Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 401–500 of 2,932
Plant as an Alternative Source of Antifungals against Aspergillus Infections: A Review
Tan, L. F., Yap, V. L., Rajagopal, M. S., Wiart, C., Selvaraja, M., Leong, M. Y., & Tan, P. L. (2022) · Plants · doi:10.3390/plants11223009 · Cited by 49
“Recent global estimates have also reported 3 million cases of chronic pulmonary aspergillosis, while more than 300,000 cases were identified for invasive aspergillosis [22].”
BackgroundHashem, A. H., Al-Askar, A. A., Saeb, M. R., Abd-Elsalam, K. A., El-Hawary, A. S., & Hasanin, M. S. (2023) · RSC Advances · doi:10.1039/d3ra03260d · Cited by 37
Fungi in a One Health Perspective
Simões, D., de Andrade, E., & Sabino, R. (2023) · Encyclopedia · doi:10.3390/encyclopedia3030064 · Cited by 46
“Cryptococcal meningitis accounts for 152,000 cases of cryptococcal meningitis, resulting in 112,000 cryptococcal-related deaths worldwide [14,63].”
BackgroundInfluentialMulti-omics characterization of the necrotrophic mycoparasite Saccharomycopsis schoenii
Junker, K., Chailyan, A., Hesselbart, A., Forster, J., & Wendland, J. (2019) · PLOS Pathogens · doi:10.1371/journal.ppat.1007692 · Cited by 34
Retinoids in Fungal Infections: From Bench to Bedside
Cosio, T., Gaziano, R., Zuccari, G., Costanza, G., Grelli, S., Francesco, P. D., Bianchi, L., & Campione, E. (2021) · Pharmaceuticals · doi:10.3390/ph14100962 · Cited by 40
“In the last 20 years, the incidence of invasive fungal infections (IFI) has increased significantly [1].”
BackgroundEl-Didamony, S. E., Kalaba, M. H., El‐Fakharany, E. M., Sultan, M. H., & Sharaf, M. H. (2022) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-022-03425-y · Cited by 38
Fan, X., Tsui, C. K. M., Chen, X., Wang, P., Liu, Z.-J., & Yang, C. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1125241 · Cited by 36
Takano, T., Kudo, H., Eguchi, S., Matsumoto, A., Oka, K., Yamasaki, Y., Takahashi, M., Koshikawa, T., Takemura, H., Yamagishi, Y., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1113401 · Cited by 41
“Fungal diseases cause considerable morbidity and mortality, resulting in a high economic burden (Drgona et al., 2014; Bongomin et al., 2017).”
BackgroundGamil, Y., Hamed, M. G., Elsayed, M. M., Essawy, A. M., Mohamed, S. M., Zayed, S., & Ismail, R. M. (2024) · BMC Oral Health · doi:10.1186/s12903-024-03952-0 · Cited by 44
“Furthermore, oral candidiasis can affect many parts of the oral mucosa such as palate, gingiva, tongue, buccal or/and labial mucosa and may also affect the oro-pharyngeal causing dysphagia [7, 8].”
BackgroundGemeda, N., Tadele, A., Lemma, H., Girma, B., Addis, G., Tesfaye, B., Abebe, A., Gemechu, W., Yirsaw, K., Teka, F., et al. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/9812093 · Cited by 38
Epidemiology of Aspergillus species causing keratitis in Mexico
Al‐Hatmi, A. M. S., Castro, M. A., de Hoog, S., Badali, H., Flores-Alvarado, V., Verweij, P. E., Meis, J. F. G. M., & Zago, V. V. (2018) · Mycoses · doi:10.1111/myc.12855 · Cited by 34
Lee, M., Huang, H.-L., Chen, L.-C., Yang, H., Ko, J., Cheng, M., Chong, I., Lee, L., Wang, J., & Dimopoulos, G. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.12.009 · Cited by 38
Advances in Fungal Peptide Vaccines
da Silva, L. B. R., Taborda, C. P., & Nosanchuk, J. D. (2020) · Journal of Fungi · doi:10.3390/jof6030119 · Cited by 35
“5 million of these dying [16,161,162], it is imperative that vaccine development be accelerated to combat these diseases.”
BackgroundWang, X., Caffrey-Carr, A. K., Liu, K.-W., Espinosa, V., Croteau, W., Dhingra, S., Rivera, A., Cramer, R. A., & Obar, J. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000802 · Cited by 34
Candida auris Urinary Tract Infections and Possible Treatment
Griffith, N. C., & Danziger, L. H. (2020) · Antibiotics · doi:10.3390/antibiotics9120898 · Cited by 48
“The etiologic agents of these infections may either be fungi or bacteria [3].”
BackgroundAntifungal promising agents of zinc(II) and copper(II) derivatives based on azole drug
de Azevedo-França, J. A., Borba-Santos, L. P., Pimentel, G. D. A., Franco, C. H. J., Souza, C., Celestino, J. D. A., de Menezes, E. F., dos Santos, N. P., Vieira, E. G., Ferreira, A. M. D. C., et al. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111401 · Cited by 35
Recent advances in fungal serine protease inhibitors
Burchacka, E., Pięta, P., & Łupicka‐Słowik, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112523 · Cited by 37
Yassin, M. T., Mostafa, A. A.-F., Al-Askar, A. A., & Al-Otibi, F. O. (2022) · Crystals · doi:10.3390/cryst12060816 · Cited by 40
In Fungal Intracellular Pathogenesis, Form Determines Fate
May, R. C., & Casadevall, A. (2018) · mBio · doi:10.1128/mbio.02092-18 · Cited by 33
Eldesouky, H. E., Salama, E. A., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-62976-y · Cited by 33
Sporotrichosis in Children: Case series and Narrative Review
Queiroz‐Telles, F., Bonifáz, A., Cognialli, R. C. R., et al. (2022) · Current Fungal Infection Reports · doi:10.1007/s12281-022-00429-x · Cited by 33
“average [20], which could be explained by the difficulty of children expressing symptoms and parental care [17–20]. Osteoarticular disease is uncommon; it is caused by direct inoculation or hematogenous spread [17]. Pulmonary infec‐ tion, disseminated disease, and meningitis are extremely rare, occurring mostly in pat…”
BackgroundMethodInfluentialPfaller, M. A., Huband, M. D., Rhomberg, P. R., Bien, P. A., & Castanheira, M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01028-22 · Cited by 37
Liu, X., Fang, R., Feng, R., Li, Q., Su, M., Hou, C., Zhuang, K., Dai, Y., Lei, N., Jiang, Y., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100887 · Cited by 38
Mikulska, M., Furfaro, E., Carolis, E. D., Drago, E., Pulzato, I., Borghesi, M. L., Zappulo, E., Raiola, A. M., Grazia, C. D., Bono, V. D., et al. (2019) · Medical Mycology · doi:10.1093/mmy/myz002 · Cited by 33
Weaver, D., Gago, S., Bromley, M., & Bowyer, P. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00347-5 · Cited by 38
Self-citationReassessing therapeutic antibodies for neglected and tropical diseases
van Huijsduijnen, R. H., Kojima, S., Carter, D. A., Okabe, H., Sato, A., Akahata, W., Wells, T. N. C., & Katsuno, K. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007860 · Cited by 39
“Pneumocystis, like Cryptococcus, is an important opportunistic pathogen in HIV/AIDS and other immunosuppressed patient populations, with estimates of up to 500,000 cases per year [87].”
BackgroundChitosan Ameliorates Candida auris Virulence in a Galleria mellonella Infection Model
Arias, L. S., Butcher, M. C., Short, B., McKloud, E., Delaney, C., Kean, R., Monteiro, D. R., Williams, C., Ramage, G., & Brown, J. L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-20 · Cited by 39
“Fungal diseases are highly prevalent; nearly a billion people worldwide are estimated to have skin, nail, and hair fungal infections (1).”
BackgroundMondal, A. H., Yadav, D., Ali, A., Khan, N., Jin, J., & Haq, Q. M. R. (2020) · Biomolecules · doi:10.3390/biom10060944 · Cited by 36
“is the most common pathogen, which is accountable for most of the infections [12].”
BackgroundKwizera, R., Katende, A., Bongomin, F., Nakiyingi, L., & Kirenga, B. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02721-9 · Cited by 36
“CPA affects an estimated 3 million people worldwide [6, 7] and 62,000 people in Uganda [8].”
BackgroundSelf-citationTong, X., Liu, T., Jiang, K., Wang, D., Liu, S., Wang, Y., & Fan, H. S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756237 · Cited by 35
“However, it likely represents only 50–60% of actual cases (1).”
BackgroundFungal Colonization and Infections—Interactions with Other Human Diseases
Mahalingam, S. S., Jayaraman, S., & Pandiyan, P. (2022) · Pathogens · doi:10.3390/pathogens11020212 · Cited by 40
Galia, L., Pezzani, M. D., Compri, M., Callegari, A., Rajendran, N. B., Carrara, E., Tacconelli, E., & the COMBACTE MAGNET EPI-Net Network (2022) · Journal of Fungi · doi:10.3390/jof8030249 · Cited by 38
Ormsby, M. J., Akinbobola, A., & Quilliam, R. S. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.163093 · Cited by 37
Targeting intrinsic cell death pathways to control fungal pathogens
Kulkarni, M., Stolp, Z. D., & Hardwick, J. M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.01.012 · Cited by 32
“Another three million live with chronic pulmonary aspergillosis, while over 10% of the world population has non-invasive fungal infections [2,3].”
Bridging the knowledge gap on mycoses in Africa: Setting up a Pan‐African Mycology Working Group
Oladele, R. O., Akase, I. E., Fahal, A. H., Govender, N. P., Hoenigl, M., Gangneux, J., Chiller, T. M., Denning, D. W., Cornely, O. A., & Chakrabarti, A. (2019) · Mycoses · doi:10.1111/myc.13044 · Cited by 37
“This is due to (1) extensive work that has been done and is still on-going by van de Sande and Fahal research teams (mycetoma in Sudan) which has led to the establishment of a WHO Collaborating Centre in Sudan; (2) The relationship of HIV/AIDS (sub-Saharan Africa bears a significant part of the burden globally) and cr…”
Self-citationTracing the Origin of Invasive Fungal Infections
Papon, N., Bougnoux, M., & d’Enfert, C. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2020.01.007 · Cited by 42
Ferric reductase-related proteins mediate fungal heme acquisition
Roy, U., Yaish, S., Weissman, Z., Pinsky, M., Dey, S., Horev, G., & Kornitzer, D. (2022) · eLife · doi:10.7554/elife.80604 · Cited by 32
Toor, A., Culibrk, L., Singhera, G. K., Moon, K.-M., Prudova, A., Foster, L. J., Moore, M. M., Dorscheid, D. R., & Tebbutt, S. J. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209652 · Cited by 32
Hossain, S., Lash, E., Veri, A. O., & Cowen, L. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108781 · Cited by 31
“albicans imposes a major burden on human health, causing ~700,000 deaths per year globally because of invasive candidiasis (Bongomin et al., 2017).”
BackgroundPhytol-Loaded Solid Lipid Nanoparticles as a Novel Anticandidal Nanobiotechnological Approach
Lima, T. L. C., de Souza, L. B. F. C., Tavares-Pessoa, L. C. S., Silva, A. M. D. S., Cavalcante, R. S., de Araujo-Junior, R. F., Cornélio, A. M., Fernandes‐Pedrosa, M. D. F., Chaves, G. M., & da Silva-Júnior, A. A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090871 · Cited by 44
“In the last few decades it is estimated that more than 150 million individuals develop severe fungal diseases every year, resulting in high rates of morbidity and mortality [1].”
BackgroundPhosphoglucose Isomerase Is Important for Aspergillus fumigatus Cell Wall Biogenesis
Zhou, Y., Yan, K., Qin, Q., Raimi, O. G., Du, C., Wang, B., Ahamefule, C. S., Kowalski, B., Jin, C., van Aalten, D. M. F., et al. (2022) · mBio · doi:10.1128/mbio.01426-22 · Cited by 38
Quek, Z. B. R., & Ng, S. H. (2024) · Pathogens · doi:10.3390/pathogens13040275 · Cited by 31
“With over a million deaths per year being fungal-related [176], more attention should be paid to the knowledge, treatment, and control of fungal pathogens [177,178], which can be augmented by judicious bait design and HC techniques (see also Section 5.1 Bait Design).”
InfluentialFungal diversity in the soil Mycobiome: Implications for ONE health
Yiallouris, A., Pana, Z. D., Marangos, G., Tzyrka, I., Karanasios, S., Georgiou, I., Kontopyrgia, K., Triantafyllou, E., Seidel, D., Cornely, O. A., et al. (2024) · One Health · doi:10.1016/j.onehlt.2024.100720 · Cited by 48
“…over 300 million individuals worldwide are afflicted by severe fungal infections and nearly 1.5 million people die from these diseases annually [6], there is an increasing need to be aware of the importance of addressing emerging health threats, antifungal resistance, and fungal infection…”
BackgroundInfluentialNanoparticle-based antifungal therapies innovations mechanisms and future prospects
Wu, Q., Cen, F., Xie, Y., Ning, X., Wang, J., Lin, Z., & Huang, J. (2025) · PeerJ · doi:10.7717/peerj.19199 · Cited by 41
“…burden of fungal diseases, six pathogens— Aspergillus , Candida , Cryptococcus , Pneumocystis jirovecii , Histoplasma capsulatum , and Mucormycetes —persist as the leading culprits of severe infections, collectively accounting for the majority of morbidity and mortality ( Bongomin et al., 2017 ).”
Takazono, T., Ito, Y., Tashiro, M., Nishimura, K., Saijo, T., Yamamoto, K., Imamura, Y., Miyazaki, T., Yanagihara, K., Mukae, H., et al. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00095-19 · Cited by 33
“The number of CPA patients is estimated to be up to 3,000,000 per year worldwide (8); however, some CPA cases are considered to be undiagnosed in resource-limited countries, and therefore, point-of-care (POC) diagnostic methods are required (9).”
BackgroundPDR-like ABC systems in pathogenic fungi
Moréno, A., Banerjee, A., Prasad, R., & Falson, P. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2019.09.002 · Cited by 37
Epidemiology of Dermatophyte and Non-Dermatophyte Fungi Infection in Ethiopia
Araya, S., Tesfaye, B., & Fente, D. (2020) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s246183 · Cited by 36
“soudanense, distributed in Africa.(7,8) Geographic location, health care, immigration, climate (temperature, humidity, wind, etc.”
InfluentialScott, J., Sueiro-Olivares, M., Thornton, B. P., Owens, R. A., Muhamadali, H., Fortune‐Grant, R., Thomson, D. D., Thomas, R., Hollywood, K. A., Doyle, S., et al. (2020) · mBio · doi:10.1128/mbio.01985-20 · Cited by 34
“reaching more than 80, 40, 50, and 30%, respectively (2, 5).”
BackgroundImmunotherapeutic approaches for fungal infections
Williams, T. J., Harvey, S., & Armstrong-James, D. P. H. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.09.007 · Cited by 35
Guo, F. Y., Zheng, C. J., Wang, M., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100122 · Cited by 32
Adole, V. A., More, R. A., Jagdale, B. S., Pawar, T. B., Chobe, S. S., Shinde, R. A., Dhonnar, S. L., Koli, P. B., Patil, A. V., Bukane, A. R., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105259 · Cited by 32
Butassi, E., Svetaz, L. A., Carpinella, M. C., Efferth, T., & Zacchino, S. A. (2021) · Antibiotics · doi:10.3390/antibiotics10091053 · Cited by 43
“Introduction In recent decades, fungi has emerged as a major cause of life-threatening invasive human infections, in particular among immunocompromised patients [1–3], particularly those with human immunodeficiency virus (HIV), cancer patients receiving chemotherapy, transplant recipients, extremely aged persons and s…”
BackgroundApplication of Non-Thermal Plasma to Fungal Resources
Veerana, M., Yu, N.-N., Ketya, W., & Park, G. (2022) · Journal of Fungi · doi:10.3390/jof8020102 · Cited by 32
Harnessing the Immune Response to Fungal Pathogens for Vaccine Development
Rivera, A., Lodge, J. K., & Xue, C. (2022) · Annual Review of Microbiology · doi:10.1146/annurev-micro-041020-111511 · Cited by 39
Novel Therapies for Biofilm-Based Candida spp. Infections
Černáková, L., Light, C. J., Salehi, B., Rogel-Castillo, C., Victoriano, M., Martorell, M., Sharifi‐Rad, J., Martins, N. A., & Rodrigues, C. F. (2019) · Advances in experimental medicine and biology · doi:10.1007/5584_2019_400 · Cited by 38
Ferric reductase-related proteins mediate fungal heme acquisition
Roy, U., Yaish, S., Weissman, Z., Pinsky, M., Dey, S., Horev, G., & Kornitzer, D. (2022) · doi:10.1101/2022.05.25.493415 · Cited by 32
Xu, J., Luo, Y., Wang, J., Tu, W., Yi, X., Xu, X., Song, Y., Tang, Y., Hua, X., Yu, Y., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1125676 · Cited by 48
“, 2012), but the social burden of serious fungal infections has influenced over 80% of the world’s population (Bongomin et al., 2017).”
BackgroundImmunomodulatory Potential of Fungal Extracellular Vesicles: Insights for Therapeutic Applications
Nenciarini, S., & Cavalieri, D. (2023) · Biomolecules · doi:10.3390/biom13101487 · Cited by 36
“Moreover, the currently used antifungal drugs are expensive, not available in every country, and have a treatment time that takes several months [48].”
BackgroundDuong, T. M. N., Nguyen, P. T., Le, T. V., Nguyen, H. L. P., Nguyen, B. N. T., Nguyen, B. T., Nguyen, T. A., Chen, S. C.-A., Barrs, V. R., Halliday, C. L., et al. (2020) · Journal of Fungi · doi:10.3390/jof6040296 · Cited by 36
“Infection, when it occurs, can result in a range of diseases; globally, the most common disease is chronic pulmonary aspergillosis (CPA), which affects more than three million people per year [1].”
BackgroundAmbati, S., Ellis, E. C., Pham, T., Lewis, Z., Lin, X., & Meagher, R. B. (2021) · mBio · doi:10.1128/mbio.00030-21 · Cited by 35
“be approximately 300,000 acute cases of aspergillosis each year (1).”
BackgroundEpidemiology, Drug Susceptibility, and Clinical Risk Factors in Patients With Invasive Aspergillosis
Wang, Y., Zhang, L., Zhou, L., Zhang, M., & Xu, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.835092 · Cited by 38
“Immunocompromised patients and those with underlying lung diseases are susceptible to IA, ranging from acute IA to chronic pulmonary aspergillosis (CPA) (5, 6).”
BackgroundUsing genomics to understand the mechanisms of virulence and drug resistance in fungal pathogens
Schikora-Tamarit, M. À., & Gabaldón, T. (2022) · Biochemical Society Transactions · doi:10.1042/bst20211123 · Cited by 35
Invasive Fungal Infections after Liver Transplantation
Senoner, T., Breitkopf, R., Treml, B., & Rajšić, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093238 · Cited by 37
“The global incidence of invasive candidiasis has been estimated to be 750,000, including 60,000–100,000 cases of intra-abdominal candidiasis, in the case of invasive aspergillosis, more than 300,000 per year [102].”
Candida diagnostic techniques: a review
Arafa, S., Elbanna, K., Osman, G. E. H., & Abulreesh, H. H. (2023) · Journal of Umm Al-Qura University for Applied Sciences · doi:10.1007/s43994-023-00049-2 · Cited by 43
Advances in Understanding Human Genetic Variations That Influence Innate Immunity to Fungi
Merkhofer, R. M., & Klein, B. S. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00069 · Cited by 36
“Perhaps the best studied gene in this regard is pentraxin 3, a soluble PRR that recognizes Aspergillus conidia (Garlanda et al., 2002).”
BackgroundInfluentialEpigenetic Regulation of Antifungal Drug Resistance
Patra, S., Raney, M., Pareek, A., & Kaur, R. (2022) · Journal of Fungi · doi:10.3390/jof8080875 · Cited by 38
“Invasive fungal infections are an increasing threat to human health worldwide, with approximately 150 million people afflicted with serious mycoses [1,2].”
BackgroundThe SSS revolution in fungal diagnostics: speed, simplicity and sensitivity
Baker, J., & Denning, D. W. (2023) · British Medical Bulletin · doi:10.1093/bmb/ldad011 · Cited by 32
“5 million deaths annually and affecting up to a billion people each year.(1) Despite this huge burden, fungal disease is underappreciated by the international medical community(2); a large and gradually expanding number of fungal infections form part of the WHO’s list of neglected tropical diseases (NTDs).”
BackgroundSelf-citationAcute Invasive Pulmonary Aspergillosis: Clinical Presentation and Treatment
Heylen, J., Vanbiervliet, Y., Maertens, J. A., Rijnders, B. J. A., & Wauters, J. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1777769 · Cited by 41
“18”
BackgroundPan-azole- and multi-fungicide-resistant Aspergillus fumigatus is widespread in the United States
Celia-Sanchez, B. N., Mangum, B., Londoño, L. G., Wang, C., Shuman, B., Brewer, M. T., & Momany, M. (2024) · Applied and Environmental Microbiology · doi:10.1128/aem.01782-23 · Cited by 33
Lawsone Unleashed: A Comprehensive Review on Chemistry, Biosynthesis, and Therapeutic Potentials
Nair, A. S., Sekar, M., Gan, S. H., Kumarasamy, V., Subramaniyan, V., Wu, Y. S., Rani, N. N. I. M., Ravi, S., & Wong, L. S. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s463545 · Cited by 41
Nanomaterial-based therapeutics for enhanced antifungal therapy
Liu, F., Chen, Y., Huang, Y., Jin, Q., & Ji, J. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb01484g · Cited by 36
Diagnosing fungal infections in clinical practice: a narrative review
Sedik, S., Wolfgruber, S., Hoenigl, M., & Kriegl, L. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2403017 · Cited by 34
“IFI are caused by opportunistic fungi species like Aspergillus , Candida , Mucorales , Cryptococcus , as well as rare molds, yeasts, and endemic mycoses [4,5].”
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways
Hetta, H. F., Melhem, T., Aljohani, H. M., Salama, A., Ahmed, R., Elfadil, H., Alanazi, F. E., Ramadan, Y. N., Battah, B., Rottura, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030364 · Cited by 35
“More than 300 million individuals worldwide are affected by severe fungal infections each year [10].”
Improving the rates ofAspergillusdetection: an update on current diagnostic strategies
Jenks, J. D., Salzer, H. J. F., & Hoenigl, M. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1558054 · Cited by 35
“mated 250,000 cases of IA [27] annually, the majority occur in immunocompromised individuals.”
BackgroundYu, L., Rodríguez-Manzano, J., Moser, N., Moniri, A., Malpartida-Cardenas, K., Miscourides, N., Sewell, T. R., Kochin, D., Brackin, A. P., Rhodes, J. L., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00843-20 · Cited by 35
“Annually, the estimated global mortality associated with fungal diseases is more than 1.6 million (2), which is 3-fold more than that of malaria and is comparable to that for tuberculosis and HIV (3, 4).”
BackgroundInfluentialA Review of the Antimicrobial Activity of Selenium Nanoparticles
Martínez–Esquivias, F., Guzmán‐Flores, J. M., Larios, A. P., Silva, N. G., & Becerra‐Ruiz, J. S. (2021) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2021.19471 · Cited by 31
Walther, G., Zimmermann, A., Theuersbacher, J., Kaerger, K., von Lilienfeld‐Toal, M., Roth, M., Kampik, D., Geerling, G., & Kurzai, O. (2021) · Journal of Fungi · doi:10.3390/jof7070511 · Cited by 42
“The disease is most prevalent in tropical and subtropical countries [2,3], but an increasing number of cases has also been reported in countries with moderate climates [4–10].”
BackgroundA new humanized antibody is effective against pathogenic fungi in vitro
Mambro, T. D., Vanzolini, T., Bruscolini, P., Perez-Gaviro, S., Marra, E., Roscilli, G., Bianchi, M., Fraternale, A., Schiavano, G. F., Canonico, B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98659-5 · Cited by 36
“(3) Third, the opsonization activity of H5K1 to C.”
BackgroundKelly, M., Pasmans, F., Muñoz, J. F., Shea, T., Carranza, S., Cuomo, C. A., & Martel, A. (2021) · Nature Communications · doi:10.1038/s41467-021-27005-0 · Cited by 39
Horta, M. A. C., Steenwyk, J. L., Mead, M. E., dos Santos, L. H. B., Zhao, S., Gibbons, J. G., Marcet‐Houben, M., Gabaldón, T., Rokas, A., & Goldman, G. H. (2022) · mBio · doi:10.1128/mbio.01519-22 · Cited by 30
“A. fumigatus is responsible for an estimated 3,000,000 cases of aspergillosis annually and more than 200,000 cases of IPA each year, reaching a mortality rate of up to 90% in the most susceptible populations (Brown et al., 2012; Bongomin et al., 2017; Firacative, 2020).”
BackgroundPoyraz, S., Döndaş, H. A., Sansano, J. M., et al. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134303 · Cited by 30
van Rhijn, N., Hemmings, S., Storer, I. S. R., Valero, C., Shuraym, H. B., Goldman, G. H., Gsaller, F., Amich, J., & Bromley, M. (2022) · mBio · doi:10.1128/mbio.02215-22 · Cited by 34
Rodríguez-Castaño, G. P., Rosenau, F., Ständker, L., & Firacative, C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030789 · Cited by 38
“It is estimated that there are more than 400,000 life-threatening Candida infections each year, with a mortality rate between 46% and 75% [9,10].”
BackgroundThe skin mycobiome and intermicrobial interactions in the cutaneous niche
Tuor, M., & LeibundGut-Landmann, S. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102381 · Cited by 30
Mahmoud, D. E., Faraag, A. H. I., & Abu El-Wafa, W. M. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03158-4 · Cited by 26
Transcriptional and translational landscape of Candida auris in response to caspofungin
Zamith-Miranda, D., Amatuzzi, R. F., Munhoz da Rocha, I. F., Martins, S. T., Lucena, A. C. R., Vieira, A. Z., Trentin, G., Almeida, F., Rodrigues, M. L., Nakayasu, E. S., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.007 · Cited by 29
Native human and mouse skin infection models to study Candida auris-host interactions
Seiser, S., Arzani, H., Ayub, T., Phan-Canh, T., Staud, C., Worda, C., Kuchler, K., & Elbe-Bürger, A. (2024) · Microbes and Infection · doi:10.1016/j.micinf.2023.105234 · Cited by 29
Franconi, I., & Lupetti, A. (2023) · Journal of Fungi · doi:10.3390/jof9121188 · Cited by 46
“Fungal infections are on the rise in recent years, as the population at risk of acquiring such infections is dramatically increasing [1,2].”
BackgroundInvasive Candidiasis: Epidemiology and Risk Factors
Cortés, J. A., & Corrales, I. F. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81813 · Cited by 34
Galgóczy, L., Yap, A., & Marx, F. (2019) · Israel Journal of Chemistry · doi:10.1002/ijch.201800168 · Cited by 29
A novel, quorum sensor-infused liposomal drug delivery system suppresses Candida albicans biofilms
Bandara, N., Hewavitharana, A. K., Shaw, P. N., Smyth, H. D. C., & Samaranayake, L. P. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119096 · Cited by 32
Sheam, M. M., Haque, Z., & Nain, Z. (2020) · Journal of Advanced Biotechnology and Experimental Therapeutics · doi:10.5455/jabet.2020.d112 · Cited by 44
“Although most of them are curable, the mortality rate of fungal diseases is similar to tuberculosis [26].”
BackgroundRasheed, M., Battu, A., & Kaur, R. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1792773 · Cited by 33
Dudhipala, N. R., Youssef, A. A. A., & Banala, N. (2020) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2020.104981 · Cited by 29
Ленгерт, Е. В., Talnikova, E. E., Tuchin, V. V., & Svenskaya, Y. I. (2020) · Skin Pharmacology and Physiology · doi:10.1159/000511038 · Cited by 30
Knoll, M. A., Ulmer, H., & Lass‐Flörl, C. (2021) · Journal of Fungi · doi:10.3390/jof7010063 · Cited by 33
“5 million deaths per year are caused by fungal infections, which is comparable to the annual mortality rates of malaria and tuberculosis [1,2].”
BackgroundFungal-Induced Programmed Cell Death
Williams, T. J., Gonzales-Huerta, L. E., & Armstrong-James, D. P. H. (2021) · Journal of Fungi · doi:10.3390/jof7030231 · Cited by 31
Kato, I., Ukai, Y., Kondo, N., Nozu, K., Kimura, C., Hashimoto, K., Mizusawa, E., Maki, H., Naito, A., & Kawai, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00883 · Cited by 30
Sporulation environment drives phenotypic variation in the pathogen Aspergillus fumigatus
Kang, S., Celia-Sanchez, B. N., Bensasson, D., & Momany, M. (2021) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkab208 · Cited by 30
Epidemiology of Candidemia in Kuwait: A Nationwide, Population-Based Study
Alobaid, K., Ahmad, S., Asadzadeh, M., Mokaddas, E. M., Al‐Sweih, N., Benwan, K. A., Alfouzan, W. A., Al‐Obaid, I., Jeragh, A., Al-Roomi, E., et al. (2021) · Journal of Fungi · doi:10.3390/jof7080673 · Cited by 35
“The highest incidence rate of 89.1 cases per 100,000 was detected among neonates/infants, followed by 62.46 cases per 100,000 for the elderly (≥65 years old) in Kuwait, while the data from the USA showed the highest incidence rate of 20.1 cases per 100,000 among the elderly [54].”
BackgroundInfluential
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.